Rozanolixizumab is a recombinant humanized monoclonal antibody and an important biologic active pharmaceutical ingredient belonging to the class of neonatal Fc receptor (FcRn) inhibitors. It is an IgG4P antibody designed to bind the human FcRn and reduce circulating immunoglobulin G (IgG). Rozanolixizumab is used in pharmaceutical products for the treatment of generalized myasthenia gravis (gMG) in eligible adult patients. The European Medicines Agency classifies rozanolixizumab as an immunosuppressant and FcRn inhibitor under ATC code L04AL02.
Rozanolixizumab is also known by development and product-related names including UCB7665, UCB-7665 and rozanolixizumab-noli. The FDA identifies the substance as a recombinant, humanized IgG4P monoclonal antibody. It is expressed using a genetically engineered Chinese hamster ovary (CHO) DG44 cell line. The FDA-approved product information gives an approximate molecular weight of 148 kDa for rozanolixizumab-noli.
The FDA Substance Registration System identifies CAS Number 1584645-37-3 for rozanolixizumab. Because this is a complex recombinant antibody rather than a conventional small molecule, its molecular characterization is better represented through molecular weight, amino-acid sequence, higher-order structure, glycosylation profile and other biologic-quality attributes rather than relying only on a traditional molecular formula.
Rozanolixizumab binds specifically to the neonatal Fc receptor (FcRn). FcRn normally participates in the recycling and protection of IgG from degradation. By blocking FcRn, rozanolixizumab promotes increased catabolism of circulating IgG, including pathogenic IgG autoantibodies. This mechanism provides the pharmacological basis for its use in antibody-mediated autoimmune disease.
As a therapeutic monoclonal antibody, Rozanolixizumab API requires specialized biologics manufacturing and quality-control processes. Important quality attributes can include identity, purity, aggregation, charge variants, glycosylation, potency, host-cell proteins, residual host-cell DNA, endotoxin, bioburden and other process- and product-related impurities.
Rozanolixizumab is used in pharmaceutical products for adults with generalized myasthenia gravis who are positive for anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibodies. The EMA lists Rystiggo as an add-on to standard therapy for these patients.
The FDA-approved product is administered by subcutaneous infusion. The current U.S. label describes a concentration of 140 mg/mL and single-dose vial presentations containing 280 mg/2 mL, 420 mg/3 mL, 560 mg/4 mL and 840 mg/6 mL. These are finished-product specifications and should not be confused with the drug-substance API specification.
Quality control for Rozanolixizumab API requires biologics-specific analytical methods. Identity may be evaluated using peptide mapping, mass spectrometry, electrophoretic methods and other validated techniques. Purity and aggregation can be assessed by chromatographic and size-based analytical methods, while potency requires a suitable validated biological or binding assay.
Because Rozanolixizumab is a complex monoclonal antibody, conventional small-molecule tests such as melting point, specific rotation and residue on ignition are generally not appropriate primary release tests. Similarly, numerical limits for individual impurities and total impurities should be taken from the applicable approved drug-substance specification rather than being invented as generic API values.
Rozanolixizumab API is a specialized biologic drug substance requiring controlled cell-culture, purification and analytical processes. Pharmaceutical development and manufacturing programs may require comprehensive quality documentation, validated analytical testing and regulatory support appropriate for recombinant monoclonal antibodies.
Typical documentation may include a Certificate of Analysis (CoA), specification sheet, Safety Data Sheet, batch documentation, stability information and applicable regulatory documentation, depending on customer and market requirements.
Storage requirements for Rozanolixizumab drug substance should follow the validated stability program and approved drug-substance specification. Finished Rystiggo product information requires protection from light and specifies refrigerated storage conditions, but these finished-product conditions should not automatically be transferred to the API drug substance specification.
Rozanolixizumab is a specialized FcRn-targeting monoclonal antibody with an established clinical and regulatory role in generalized myasthenia gravis. Reliable manufacture requires control of identity, purity, aggregation, potency, product-related variants and process-related impurities. For this reason, a biologics-specific quality system and analytical strategy are essential for consistent Rozanolixizumab API manufacturing.
| Parameter | Specification |
|---|---|
| Appearance | white to off-white crystalline powder |
| Identification | IR & HPLC compliant |
| Assay (HPLC) | 98.0% – 102.0% |